Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy
Authors' conclusion
In this study, [177Lu]Lu-DOTAGA.FAPi dimer therapy showed promising safety and efficacy in aggressive, radioiodine-resistant thyroid cancer, achieving a median PFS and OS of 29 and 32 months, respectively, with manageable adverse events.
Study context
- Population
- Patients with radioiodine-resistant (RAI-R) follicular cell-derived thyroid carcinoma after multiple lines of previous treatments; 37 female, 36 male; mean age 54.3 years (range 27–80)
- Participants
- 73 patients
- Exposure
- [177Lu]Lu-DOTAGA.FAPi dimer monotherapy vs Tandem [177Lu]Lu/[225Ac]Ac-DOTAGA.FAPi dimer
- [177Lu]Lu-DOTAGA.FAPi dimer monotherapyn = 65
- Tandem [177Lu]Lu/[225Ac]Ac-DOTAGA.FAPi dimern = eight
- Outcome
- PFS and OS
Methodological detailsMedian cumulative activity 22.2 GBq (range, 4 GBq-55.5 GBq) over one to nine cycles, median three cycles
- Median cumulative activity 22.2 GBq (range, 4 GBq-55.5 GBq) over one to nine cycles, median three cycles
Main finding
As reported in the abstract
- Median progression-free survival (PFS)
- 29 months [CI 14-34 months]
- Median overall survival (OS)
- 32 months [CI 21-40 months]
- Disease progression
- 19 patients
- Deaths
- 20
- Deaths due to thyroid cancer
- 16
Observational data: associations, not effects.
Safety
Adverse events (CTCAE V5.0)
Patients
- Grade III anemia (primarily linked to bone metastasis in three cases and neck tumor mass bleed in one)
- 4 (5.4%)
- Grade III thrombocytopenia
- 3 (4%)
- No grade III renal or hepatotoxicity was observed
Original publication
Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy. Thyroid. Published 27 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →